SCROLL DOWN

Better Therapy Brighter Outlook
LT3001

tPA is the only drug approved to treat stroke with serious side effects and unsatisfactory outcomes.

  • <3hr is eligible to receive tPA

  • Actual usage of tPA 3%~5%

  • High risk of hemorrhage

LT3001, a novel molecule designed to restore occluded blood flow without causing hemorrhage, holds promise as a superior and safer therapy to expand the treatable population and improved the outcome after acute ischemic stroke.

NEWS
Corporate

2021.09.05

Lumosa CEO's Interview by Kevin Price on the Price of Business Show
Corporate

2021.08.03

Lumosa Therapeutics Announces Positive Result from LT3001 Phase 2A Clinical Trial in Acute Ischemic Stroke
Corporate

2021.06.23

Lumosa and DONGWHA Enter Exclusive Distributorship Agreement for LT1001 in Korea – Securing a Foot in Northeast Asia and Increase Global Licensing Value
Corporate

2021.06.16

Formulation Patent for LT1001, An Extended-Release Analgesic Injection, Granted by Chinese Patent Office
Corporate

2021.05.25

Lumosa and Darnitsa Enter into Distribution Agreement in Ukraine for LT1001, an Extended-Release Analgesic Injection
Corporate

2021.02.01

LT3001 Compound Patent Approved in Korea and Europe
Corporate

2020.12.17

Naldebain Approved by Singapore HSA
Corporate

2020.12.14

Lumosa to commence a multi-dose Phase 1 trial right after the single-dose Phase 2 to expand stroke treatment methodology
Corporate

2020.12.04

Enrollment Completed for 1st Phase 2 Trial for LT3001
Corporate

2020.09.14

LT3001 Received IND Approval from China's NMPA
Corporate

2020.08.10

Patent for Lumosa's Extended-Release Analgesic Granted by Taiwan IPO
Corporate

2020.03.02

The US FDA has granted the Orphan Drug Status to Lumosa's LT2003, an anti-tumor targeting fusion protein, for the treatment of pancreatic cancer

Learn More

Investors

Learn More